EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

SGLT2 Inhibitor Use in Type 2 Diabetes in England: A Population‐Based Cross‐Sectional Study of Uptake of NICE Guidance

Patrick Muller iD, Jonathan Wray, Muksitur Rahman, James Hawkins, Chirag Bakhai iD, Daniel J Cuthbertson iD, Robert Willans, Eleanor Yelland iD, Shaun Rowark, Magdalena Watras, Luke Sheridan Rains iD, Amanda I Adler iD und 1 weitere

Diabetes, Obesity and Metabolism · 2026

DOI: 10.1111/dom.71010 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Patrick Muller und 12 weiteren Autor:innen. Beteiligte Einrichtung: National Institute for Health and Care Excellence, Manchester, UK. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Guideline Adherence. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIHR Oxford Biomedical Research Centre.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

An update to the NICE Type 2 diabetes (T2DM) guideline in February 2022 recommended an SGLT2 inhibitor be offered to people with cardiovascular disease (CVD) or heart failure (HF) as comorbidities and considered for people at high CVD risk. We report uptake of this guideline in England 18 months after its publication. Materials and Methods Observational cohort study using Clinical Practise Research Data Link records linked to hospital admissions. Presence of a current prescription for an SGLT2 inhibitor was evaluated in people with T2DM on 1 September 2023, stratified by CVD category (CVD only; HF only; both; high CVD risk; low CVD risk) and chronic kidney disease status, and by age, gender, ethnicity, deprivation and T2DM duration. Adjusted associations between patient characteristics and uptake were evaluated using logistic regression.

Results

In the cohort of 587 826 people with T2DM, the percentage with a current prescription was 19.5% for people with CVD, 29.4% for people with HF, 30.5% for people with both CVD and HF, and 19.9% and 20.2% respectively for people at high and low CVD risk. In age‐stratified analyses, uptake was higher in people with more comorbidities. In adjusted models, uptake was lower in people aged > 60, women, Black people and people living in areas of higher deprivation.

Conclusions

Whilst prescribing of SGLT2 inhibitors continues to rise in England, recent trends indicate an opportunity remains to increase uptake. Action is necessary to address inequalities by ethnicity and deprivation, and lower uptake for people with T2DM and CVD without HF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Sodium-Glucose Transporter 2 InhibitorsGuideline AdherenceHumansFemaleCross-Sectional StudiesEnglandAgedMaleMiddle AgedCardiovascular DiseasesHeart FailurePractice Guidelines as TopicCohort StudiesAdultComorbidity

Stichwörter der Autor:innen

SGLT2 inhibitorcardiovascular diseasecohort studyheart failurepharmaco‐epidemiologypopulation study

Substanzen

Sodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • National Institute for Health and Care Excellence, Manchester, UK.
  • NHS Bedfordshire Luton and Milton Keynes Integrated Care Board, Luton, UK.
  • NHS England, Leeds, UK.
  • Obesity and Endocrinology Research Group, Institute of Ageing and Chronic Diseases, University of Liverpool, Liverpool, UK.
  • Oxford Centre for Diabetes Endocrinology and Metabolism, University of Oxford, Oxford, UK.

ORCID-Profile: Patrick Muller, Chirag Bakhai, Daniel J Cuthbertson, Eleanor Yelland, Luke Sheridan Rains, Amanda I Adler

Förderung

  • NIHR Oxford Biomedical Research Centre

Zitieren

APA

Muller, P., Wray, J., Rahman, M., Hawkins, J., Bakhai, C., Cuthbertson, D. J., Willans, R., Yelland, E., Rowark, S., Watras, M., Sheridan Rains, L., Adler, A. I., & Owen, L. (2026). SGLT2 Inhibitor Use in Type 2 Diabetes in England: A Population‐Based Cross‐Sectional Study of Uptake of NICE Guidance. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.71010

Vancouver

Muller P, Wray J, Rahman M, Hawkins J, Bakhai C, Cuthbertson DJ, et al. SGLT2 Inhibitor Use in Type 2 Diabetes in England: A Population‐Based Cross‐Sectional Study of Uptake of NICE Guidance. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.71010

BibTeX
@article{Muller2026,
  author = {Muller, Patrick and Wray, Jonathan and Rahman, Muksitur and Hawkins, James and Bakhai, Chirag and Cuthbertson, Daniel J and Willans, Robert and Yelland, Eleanor and Rowark, Shaun and Watras, Magdalena and Sheridan Rains, Luke and Adler, Amanda I and Owen, Lesley},
  title = {SGLT2 Inhibitor Use in Type 2 Diabetes in England: A Population‐Based Cross‐Sectional Study of Uptake of NICE Guidance},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.71010}
}
Kostenlos starten →